Antineoplastic Agents, Phytogenic

"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Descriptor ID	D000972
MeSH Number(s)	D27.505.954.248.179
Concept/Terms	Antineoplastic Agents, Phytogenic Antineoplastic Agents, Phytogenic Agents, Phytogenic Antineoplastic Phytogenic Antineoplastic Agents Antineoplastics, Phytogenic Phytogenic Antineoplastics Antineoplastics, Botanical Botanical Antineoplastics

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Phytogenic [D27.505.954.248.179]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Phytogenic".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.

Bar chart showing 74 publications over 26 distinct years, with a maximum of 6 publications in 1998

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1996	2	0	2
1997	2	0	2
1998	4	2	6
1999	3	0	3
2000	1	0	1
2001	4	0	4
2002	1	1	2
2003	2	1	3
2004	3	1	4
2005	1	3	4
2006	2	0	2
2007	1	0	1
2008	3	1	4
2009	1	0	1
2010	3	0	3
2011	2	0	2
2012	1	2	3
2013	2	0	2
2014	4	1	5
2015	4	0	4
2016	1	2	3
2017	3	1	4
2018	1	2	3
2019	3	1	4
2020	1	0	1

Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.

Subramaniyan B, Rajaputra P, Nguyen L, Li M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y. Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Photochem Photobiol. 2020 05; 96(3):668-679.

View in: PubMed
Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. J Control Release. 2019 08 28; 308:86-97.

View in: PubMed
Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.

View in: PubMed
Carter AC, King JB, Mattes AO, Cai S, Singh N, Cichewicz RH. Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B1. J Nat Prod. 2019 06 28; 82(6):1694-1703.

View in: PubMed
Teekaraman D, Elayapillai SP, Viswanathan MP, Jagadeesan A. Quercetin inhibits human metastatic ovarian cancer cell growth and modulates components of the intrinsic apoptotic pathway in PA-1?cell line. Chem Biol Interact. 2019 Feb 25; 300:91-100.

View in: PubMed
Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK, Aghajanian C. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2019 03; 152(3):548-553.

View in: PubMed
Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 12; 151(3):422-427.

View in: PubMed
Ola ARB, Risinger AL, Du L, Zammiello CL, Peng J, Cichewicz RH, Mooberry SL. Taccalonolide Microtubule Stabilizers Generated Using Semisynthesis Define the Effects of Mono Acyloxy Moieties at C-7 or C-15 and Disubstitutions at C-7 and C-25. J Nat Prod. 2018 03 23; 81(3):579-593.

View in: PubMed
Babu A, Amreddy N, Muralidharan R, Pathuri G, Gali H, Chen A, Zhao YD, Munshi A, Ramesh R. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci Rep. 2017 11 07; 7(1):14674.

View in: PubMed
Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.

View in: PubMed

People

Explore

Similar Concepts

Top Journals